The European Pharmaceutical Market is projected to grow from €169 Billion in 2015 to €206 Billion in 2022. (source). One of the 20th century's most innovative pharmaceutical researchers - Dr. Paul Janssen - first established Janssen Pharmaceutica N.V. in Europe more than six decades ago and lay the foundation for the discovery and development of more than 80 new medicines. That Belgian biotech industry alone funneled €3.4 billion into research and development in 2016, a staggering increase of 123% compared to 10 years earlier.
In celebration of and collaboration with these strides in human healthcare, Johnson & Johnson Innovation Limited and Johnson & Johnson Innovation, JLABS have launched the European Innovation QuickFire Challenge. The innovator with the best idea, technology, or solution that improves human healthcare and impacts the European ecosystem will receive up to €100,000 in grants as well as a voucher for one year of residency at an available JLABS locations, including a laboratory bench, workstation and access to the global JLABS community.
JLABS is continuing to expand towards a truly global open innovation ecosystem by nurturing breakthrough science at a growing network of JLABS locations, including upcoming launches spanning from New York City to Shanghai. This unique model provides entrepreneurs with access to state-of-the-art infrastructure, expertise, and funding opportunities in a no-strings-attached environment.
Rewards and benefits
- 1 year residency at an available JLABS locations
- Access to the global JLABS network
Areas of Interest
We encourage applications from companies working on all aspects of human healthcare, and have a particular interest in the following areas:
- Consumer products
- Medical devices
- Global public health
- Health technologies
- Cross sector initiatives
Why this challenge matters to us:
At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it's our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.
Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential impact
- Uniqueness of solution & level of competition in current market
- Quality & feasibility of technology
- Team credibility & capabilities
- Plans for utilizing JLABS residency
- Idea submission outlines interest in the innovation ecosystem in Europe
Submit your idea today!
About Johnson & Johnson Innovation, JLABS
Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.
JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. .For more information about JLABS, please visit www.jlabs.jnjinnovation.com.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation Limited focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation